NCT00705861

Study to Assess the Efficacy and Safety of SK3530 on Erectile Dysfunction in Patients With Diabetes Mellitus

A 12 Week, Multi-center, Randomized, Double Blinded, Placebo-controlled, Parallel Group, Fixed Dose Study to Assess the Efficacy and Safety of SK3530 on Erectile Dysfunction in Patients With Diabetes Mellitus

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 112 (actual)
• Sponsor: SK Chemicals Co., Ltd. · Industry
• Sex: Male
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of SK3530 on erectile dysfunction in Patients with Diabetes Mellitus.

Detailed description

SK3530 is a potent and selective phosphdiesterase type 5(PDE 5) inhibitor developed for the treatment of erectile dysfunction(ED). Since ED is common in men with Diabetes Mellitus, it is important to determine the efficacy and safety of SK3530 on erectile dysfunction in Patients with Diabetes Mellitus.

Conditions

• Erectile Dysfunction

Interventions

Type	Name	Description
DRUG	Placebo	Placebo as a substitute of SK3530 100mg
DRUG	SK3530	SK3530 100mg

Timeline

• Start date: 2007-11-01
• Primary completion: 2008-07-01
• Completion: 2008-07-01
• First posted: 2008-06-26
• Last updated: 2013-04-18

Locations

1 site across 1 country: South Korea